Cocrystal Pharma

Update in progress

COCP (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cocrystal Pharma, Inc. is a Bothell, Washington–based biotechnology company focused on antiviral therapies for serious and chronic viral diseases in the United States. Using structure-based design, it targets influenza A/B, coronaviruses (including SARS-CoV-2 and MERS), norovirus, other respiratory viruses, and hepatitis C. It develops CC-42344, a PB2 inhibitor in phase 2a, and an inhaled form for flu prophylaxis; CDI-988 (pan-viral) in phase 1; and CC-31244 for HCV in phase 2a. It licenses influenza programs from Merck and antiviral work from Kansas State University. Founded 2006.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive